Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy STAT 15h Novartis Pharma Health
Belfast biotech firm re-engages with global pharmaceutical business for ramp project Insider Media 2d Biotechnology Pharma
Amgen’s Repatha reduces heart attack risk in real-world study Clinical Trials Arena 2d Amgen Pharma Global Health
ANI to expand its rare disease portfolio with Egetis takeout Scrip Pharma Intelligence 2d FDA Rare Diseases
6 biotech stocks for a volatile bull market: Jon Erlichman BNN Bloomberg 2d Bull Market Biotechnology
CBI FIR against waste management company Hanjer Biotech for defrauding bank of $10 million under guise of setting up recycling plant in UK; 2nd fraud case The Times of India 2d Biotech Mumbai India
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera Pharmaceutical Technology 4d Nxera Pharma Biotech All sources
Prediction: AbbVie's next blockbuster is hiding in a two-drug Crohn's combo The Motley Fool 6d Pharma Business (US) Movies All sources
AbbVie’s skin disease drug posts Phase III win as market competition heats up Clinical Trials Arena 12:57 Fri, 23 Oct Phase III Pharma Biotech
AbbVie bids to join the Bcma crowd with etentamig pharmaphorum 11:03 Wed, 28 Oct FDA Blood Cancer Pharma
